GGrantIndex
Sort

10,829 grants matching car t

Characterizing and Targeting the Novel IL-15- AKT-XBP1s Pathway in NK Cells

$445,687
Jianhua Yu · Beckman Research Institute/City Of Hope · R01 · FY2021 · CA

Characterizing and Targeting the Novel IL-15- AKT-XBP1s Pathway in NK Cells

$445,687
Jianhua Yu · Beckman Research Institute/City Of Hope · R01 · FY2020 · CA

Phenotypic variability within isogenic population of lymphocytes

$445,550
Gregoire Altan-Bonnet · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Brief Child Safety Interventions in Emergency Department

$445,515
Johns Hopkins University · R01 · FY2002 · HD

CAREER: Cyber-enabled Multiscale Methodology for Hybrid Soft Materials-based Nanoparticle Design

$445,401
Meenakshi Dutt · Rutgers University New Brunswick · · FY2017 · MPS

Intensive Daily Measurement of Simultaneous Alcohol and Marijuana Use in a High-Risk Community Sample of Young Adults: Impacts on Acute and Longer-term Use and Consequences

$445,026
Christine M Lee · University Of Washington · R01 · FY2017 · AA

TARGETING ROR1 WITH CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS

$444,969
Stanley R Riddell · Fred Hutchinson Cancer Research Center · R01 · FY2019 · CA

Improving genetically engineered T cells for medulloblastomas

$444,775
Giedre Krenciute · St. Jude Children'S Research Hospital · R01 · FY2021 · NS

Improving genetically engineered T cells for medulloblastomas

$444,775
Giedre Krenciute · St. Jude Children'S Research Hospital · R01 · FY2025 · NS

Improving genetically engineered T cells for medulloblastomas

$444,775
Giedre Krenciute · St. Jude Children'S Research Hospital · R01 · FY2022 · NS

Improving genetically engineered T cells for medulloblastomas

$444,775
Giedre Krenciute · St. Jude Children'S Research Hospital · R01 · FY2023 · NS

The Impact of Telelactation Services on Breastfeeding Outcomes among Minority Mothers: Siteless Tele-MILC Trial

$444,671
Lori Uscher-Pines · Rand Corporation · R01 · FY2021 · NR

Molecular modeling of G protein-coupled receptors

$444,483
Stefano Costanzi · Diabetes, Digestive, Kidney Diseases · Z01 · FY2007 · DK

Exploiting the immunomodulatory effects of sulindac and novel non-COX inhibitory derivatives for cancer treatment

$444,328
Gang Zhou · Augusta University · R01 · FY2020 · CA

Scalable Approach to Optimal Control Design for Large-dimensional Systems Using Operator Theoretic Methods

$444,199
Umesh Vaidya · Clemson University · · FY2025 · ENG

American Indian mHealth Smoking Dependence study (PQ4)

$444,040
Daniel G Petereit · Rapid City Regional Hospital · R01 · FY2012 · CA

Isoform-specific Regulation of the Coxsackie and Adenovirus Receptor in Polarized Epithelia

$444,000
Katherine Julie Excoffon · Wright State University · R15 · FY2015 · AI

Enhanced imaging and treatment of aggressive subtypes of prostate cancer

$443,607
Martin G Pomper · Johns Hopkins University · R01 · FY2022 · CA

DESIGN AND TESTING OF DUAL-TARGETED FINE-TUNED IMMUNE-RESTORING (DFIR) CAR T-CELL THERAPY TO ACHIEVE CURES OF HIGH-GRADE SEROUS OVARIAN CANCER.

$443,178
Dana-Farber Cancer Institute, Inc. · · FY2022 · Defense Health Agency

(PQ6)Nuclear receptor mechanisms in circadian disruption induced hepatocarcinogenesis

$443,175
Loning None Fu · Baylor College Of Medicine · R01 · FY2019 · CA

Ameliorating off-target toxicities of CAR T cells by engineering NOT gates

$442,900
Wendell A Lim · University Of California, San Francisco · R01 · FY2023 · CA

African Rigorous Innovative Stroke Epidemiological Surveillance (ARISES)

$442,804
Mayowa Ojo Owolabi · College Of Medicine, University Of Ibadan · R01 · FY2020 · NS

(PQ6)Nuclear receptor mechanisms in circadian disruption induced hepatocarcinogenesis

$442,560
Loning None Fu · Baylor College Of Medicine · R01 · FY2018 · CA

Conditional control of universal antigen receptor signaling

$442,414
Jason Jakob Lohmueller · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · GM

Conditional control of universal antigen receptor signaling

$442,414
Jason Jakob Lohmueller · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · GM